Home › Funds › Enavate Sciences GP, LLC › IMNM
Enavate Sciences GP, LLC position in IMNM
IMMUNOME INC COM · Health Care
Enavate Sciences GP, LLC reported holding 3,613,799 shares of IMNM (IMMUNOME INC COM) in its Q2 2026 13F filing — a position valued at US$76.6M, representing 22.17% of its reported portfolio and ranking #3 among its reported holdings. Enavate Sciences GP, LLC has disclosed IMNM holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Enavate Sciences GP, LLC's IMNM position evolved
Enavate Sciences GP, LLC first disclosed a stake in IMNM in Q4 2024 at 3,478,261 shares (US$36.9M). The position peaked in Q4 2025 at 4,768,583 shares, worth US$102.4M. Across 7 filings, Enavate Sciences GP, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 3,613,799 shares valued at US$76.6M. Notable position changes include a 37% increase in Q1 2025 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 3.48M | $36.94M | New |
| Q1 2025 | 4.77M | $32.09M | Add |
| Q2 2025 | 4.77M | $44.35M | Hold |
| Q3 2025 | 4.77M | $55.84M | Hold |
| Q4 2025 | 4.77M | $102.43M | Hold |
| Q1 2026 | 3.61M | $79.03M | Reduce |
| Q2 2026 | 3.61M | $76.58M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMNM and 13F data
IMNM (IMMUNOME INC COM) is a Health Care company. 48 other funds we track also report a position in IMNM — the largest reported positions include Redmile Group, LLC (US$104.1M), SILVERARC CAPITAL MANAGEMENT, LLC (US$42.7M), Sofinnova Investments, Inc. (US$36.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMNM
- Redmile Group, LLC 4.91M sh · $104.08M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.02M sh · $42.74M · Q2 2026
- Sofinnova Investments, Inc. 1.72M sh · $36.45M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M sh · $34.03M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 732.51K sh · $15.52M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 714.55K sh · $15.14M · Q2 2026
- Parkman Healthcare Partners LLC 594.20K sh · $12.59M · Q2 2026
- ALERUS FINANCIAL NA 383.42K sh · $8.12M · Q2 2026
- Atom Investors LP 297.49K sh · $6.30M · Q2 2026
More on Enavate Sciences GP, LLC
FAQ
How long has Enavate Sciences GP, LLC held IMNM?
Enavate Sciences GP, LLC has disclosed IMNM holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Enavate Sciences GP, LLC's current position in IMNM?
As of Q2 2026, Enavate Sciences GP, LLC holds 3.61M shares of IMNM (IMMUNOME INC COM), valued at $76.58M, representing 22.17% of its reported portfolio and ranking #3.
Has Enavate Sciences GP, LLC been buying or selling IMNM?
In the latest 13F filing (Q2 2026), Enavate Sciences GP, LLC held unchanged its position in IMNM. The position peaked in Q4 2025 at 4.77M shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Redmile Group, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, Sofinnova Investments, Inc., among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.